Biologic Agent |
|
%LDAS |
Source |
|
Abatacept after IR to anti-TNF therapy |
Induction -Month 12 |
18.3% |
ATTAIN + LTE study (Genovese 2007) |
|
Maintenance |
|
|
|
Month 18 |
24.2% |
ATTAIN + LTE study (Genovese 2007) |
|
Month 24 |
28% |
ATTAIN + LTE study (Genovese 2007) |
|
Anti-TNF agents |
Induction - Month 18 |
11% |
REACT trial (Bombardieri 2007) |
|
Maintenance - Month 24 |
21.5% |
ATTAIN reanalysis afterIR to 2 anti-TNF agents |
|
Rituximab after IR to anti-TNF therapy |
Induction -Month 12 |
18.3% |
REFLEX + LTE study (Keystone 2007) |
|
Maintenance |
|
|
|
Month 18 |
24.2% |
REFLEX + LTE study (Keystone 2007) |
|
Month 24 |
28% |
Keystone (EULAR 2007) |
|
DMARDS |
Month 24 |
5% |
Clinical experts opinion |